90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Children affected by high risk or relapsed/refractory leukaemia have a poor prognosis, with
an increased risk of relapse. These patients generally need treatment intensification and a
bone marrow transplantation (BMT).
Nevertheless, with conventional treatent the risk of relapse after transplant remains high.
Radioimmunotherapy provides a way to deliver high dose irradiation to the bone marrow (where
leukaemia resides), while sparing normal organs and tissues from its toxicity.This can be
achieved by linking a radioactive molecule (Yttrium90) to an antibody that, once infused in
the blood, targets marrow/leukemic cells.
Phase:
Phase 2
Details
Lead Sponsor:
Great Ormond Street Hospital for Children NHS Foundation Trust